Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of rheumatoid arthritis.

1,25 dihydroxy vitamin D3 has immunomodulatory functions in rheumatoid arthritis (RA) and is an anti-osteoporotic agent.

No studies exist to assess its pain-relieving action in RA.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

The primary outcome was the time to pain relief by patients' visual analogue scale (VAS).

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.

Comparisons between the groups were done by Mann-Whitney test and independent samples test.

What Was Measured

Topics PubMed links to this paper include Antirheumatic Agents, Arthritis, Rheumatoid, Calcium, Dietary, Dietary Supplements, Early Diagnosis, Health Status and Pain.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in people with rheumatoid arthritis.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (International journal of rheumatic diseases), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Rheumatoid arthritis research.